scholarly journals Nonadjunctive Use of Continuous Glucose Monitoring for Diabetes Treatment Decisions

2016 ◽  
Vol 10 (5) ◽  
pp. 1169-1173 ◽  
Author(s):  
Jessica R. Castle ◽  
Peter G. Jacobs
Keyword(s):  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Treatment Decisions ◽  
Diabetes Treatment

scholarly journals Commentary Regarding Shapiro, “Nonadjunctive Use of Continuous Glucose Monitors for Insulin Dosing: Is It Safe?”

2017 ◽  
Vol 11 (4) ◽  
pp. 839-841 ◽  
Author(s):  
David Price
Keyword(s):  
Social Media ◽  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Treatment Decisions ◽  
Diabetes Treatment ◽  
Continuous Glucose Monitors

The FDA recently expanded the approved use of Dexcom’s G5 Mobile continuous glucose monitoring (CGM) system to allow for diabetes treatment decisions. This decision is expected to reduce the burden of SMBG testing and increase the adoption and persistent use of CGM. The safety of nonadjunctive CGM use was questioned because of sporadic large discrepancies between CGM and SMBG values. These data were viewed in the context of complaints found in the FDA MAUDE database and social media postings. This commentary provides additional perspective on the inferences that can be drawn from these reports and the risk of nonadjunctive use of CGM data.

scholarly journals The Changing Landscape of Glycemic Targets: Focus on Continuous Glucose Monitoring

2020 ◽  
Author(s):  
Pamela R. Kushner ◽  
Davida F. Kruger
Keyword(s):  
Blood Glucose ◽  
Glycemic Control ◽  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Treatment Decisions ◽  
Diabetes Treatment ◽  
Good Glycemic Control ◽  
Patients With Diabetes ◽  
Time In Range ◽  
Glycemic Targets

Continuous glucose monitoring (CGM) provides comprehensive assessment of daily glucose measurements for patients with diabetes and can reveal high and low blood glucose values that may occur even when a patient’s A1C is adequately controlled. Among the measures captured by CGM, the percentage of time in the target glycemic range, or “time in range,” (typically 70–180 mg/dL) has emerged as one of the strongest indicators of good glycemic control. This review examines the shift to using CGM to assess glycemic control and guide diabetes treatment decisions, with a focus on time in range as the key metric of glycemic control.

scholarly journals The Changing Landscape of Glycemic Targets: Focus on Continuous Glucose Monitoring

2020 ◽  
Author(s):  
Pamela R. Kushner ◽  
Davida F. Kruger
Keyword(s):  
Blood Glucose ◽  
Glycemic Control ◽  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Treatment Decisions ◽  
Diabetes Treatment ◽  
Good Glycemic Control ◽  
Patients With Diabetes ◽  
Time In Range ◽  
Glycemic Targets

Continuous glucose monitoring (CGM) provides comprehensive assessment of daily glucose measurements for patients with diabetes and can reveal high and low blood glucose values that may occur even when a patient’s A1C is adequately controlled. Among the measures captured by CGM, the percentage of time in the target glycemic range, or “time in range,” (typically 70–180 mg/dL) has emerged as one of the strongest indicators of good glycemic control. This review examines the shift to using CGM to assess glycemic control and guide diabetes treatment decisions, with a focus on time in range as the key metric of glycemic control.

scholarly journals Role of Continuous Glucose Monitoring in Diabetes Treatment

2018 ◽  
Author(s):  
Irl Hirsch ◽  
Tadej Battelino ◽  
Anne Peters ◽  
James Chamberlain ◽  
Grazia Aleppo ◽  
...  
Keyword(s):  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Diabetes Treatment

scholarly journals Therapy Adjustments Based on Trend Arrows Using Continuous Glucose Monitoring Systems

2019 ◽  
Vol 13 (4) ◽  
pp. 763-773 ◽  
Author(s):  
Ralph Ziegler ◽  
Simone von Sengbusch ◽  
Jens Kröger ◽  
Oliver Schubert ◽  
Petra Werkmeister ◽  
...  
Keyword(s):  
Real Time ◽  
Continuous Glucose Monitoring ◽  
Glucose Control ◽  
Glucose Monitoring ◽  
Treatment Decisions ◽  
Individual Therapy ◽  
General Treatment ◽  
Monitoring Systems ◽  
Appropriate Treatment ◽  
Glucose Curve

Continuous glucose monitoring (CGM) systems use trend arrows to accurately display the anticipated glucose curve for the user. These are used for both “real-time” glucose monitoring and for intermittent scanning glucose monitoring. Trend arrow data are used by people with diabetes to make corrections to their glucose control. It is essential that they are correctly interpreted when adjusting insulin doses and to ensure that appropriate treatment decisions are made. The aim of this article is to provide general treatment guidance for diabetes teams and for people with diabetes using CGM in the context of trend arrows. This is based on previous recommendations for interpreting trend arrows without losing sight of the need for individual therapy adjustment.

Sign in / Sign up

Export Citation Format

Share Document